* Companies decline to comment
* Taisho's sales of OTC drugs down year-on-year in
April-Sept
(Adds details on Taisho)
Dec 16 (Reuters) - Japanese healthcare firm Taisho
Pharmaceutical Holdings Co Ltd 4581.T is said to be close to a
$1.6 billion deal for Bristol-Myers Squibb Co's BMY.N French
over-the-counter drugs business UPSA, Bloomberg reported on
Sunday, citing sources familiar with the matter.
An agreement for the consumer-health business could be
announced as soon as this week, according to the report https://bloom.bg/2QyHulF.
Bristol-Myers Squibb declined to comment on the report, but
said it was still considering options for the strategic review
of UPSA that was announced in June. A Taisho spokesman declined
to comment.
The report comes amid a flurry of deals among drugmakers,
who are trying to survive a contraction in the domestic drug
market due to government-led price cuts and promotion of generic
drugs.
The Japanese drugmaker's sales of over-the-counter drugs in
foreign markets was worth 8.8 billion yen in April-September,
down 7.9 percent on year, according to its results.
Earlier this month, Takeda Pharmaceutical 4502.T won
shareholder approval for its $59 billion takeover of
London-listed Shire SHP.L , allowing the company to join the
ranks of the world's top 10 drugmakers. urn:newsml:reuters.com:*:nL4N1YA1TD
German drugmaker Stada STAGn.D and Italian healthcare
company Angelini were among the final bidders for Bristol-Myers'
UPSA unit, according to a Reuters report in November.
urn:newsml:reuters.com:*:nL8N1XJ9IA
Taisho shares ended down 0.3 percent at 12,560 yen on
Monday.
(Reporting by Bhanu Pratap in Bengaluru; Additional reporting
by Philip George in Bengaluru; Editing by Sunil Nair)
((Bhanu.Pratap@thomsonreuters.com; (within U.S. +1 646 223
8780, outside U.S. +91 80 6749 3581);))